Clinical Trial Search

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -9.7; -17.2 Units on a scale — p=0.001

Primary: Estimated Cigarettes Taken at Free Price Derived From the Cigarette Purchase Task — 1.50; 1.45; 1.47; 1.45 Cigarettes (log transformed)

Primary: Pathological Complete Response (pCR) RCB-0 or RCB-1 — 14; 10 Participants — p=<0.01

Primary: Percentage of Participants to Learn New Information — 38.6 percentage of participants

Primary: Efficacy: Median Progression-free Survival (PFS) Rate at 6 Months (PFS-6) — 22.5; 25.0; 18.2 Percentage (%) of subjects

Primary: Mean Percent Change in Duodenal Polyp Burden — -29.6 percent change in Duodenal Polyp Burden

Primary: Disease Free Survival at 1 Year Post-transplant — 18 Participants

Primary: Change From Baseline in the 16-Item Negative Symptoms Assessment (NSA-16) — -2.7; -3.6 units on a scale — p=0.732

Primary: Average Change in Heart Rate (HR) — 6.5 beats per minute (bpm)

Primary: Pharmacokinetics: Area Under the Concentration Time Curve (AUC) of LY2140023 and LY404039 — 1420; 1360; 836; 926 nanograms*hours per milliliter (ng*h/mL)

Primary: Inflammatory Peritoneal Markers — 0.80; 1.14; 4.26; 3.24 log (pg/ml) — p=0.058

Primary: Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire — 11.1; 11.9 units on a scale

Primary: Rate of Device-related Bacteremia — 30; 11 Number of infections

Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)

Primary: Comparison of Conventional Imaging and Gallium Ga 68-edotreotide PET Using Concordance in Tumor Detection With Pathology — 28; 0; 1; 5 Participants